ArticleThe Lancet regional health. Western Pacific2026
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04923945 (A Multi-center, Open-label, Phase IIIb Confirmatory Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of Savolitinib in Treating Locally Advanced or Metastatic NSCLC Patients With MET Exon 14mutations), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-center, Open-label, Phase IIIb Confirmatory Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of Savolitinib in Treating Locally Advanced or Metastatic NSCLC Patients With MET Exon 14mutations
Who cites it
1 citing paper in PubMed.
- Long-term comparative effectiveness of tepotinib versus standard of care for MET exon 14 skipping-mutated non-small cell lung cancer.Therapeutic advances in medical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Savolitinib, a potent MET inhibitor, showed promising efficacy and tolerable safety in a Phase 3b confirmatory trial for the treatment of Chinese patients with non-small cell lung cancer (NSCLC) harbouring MET exon 14 ( Methods: This multicentre, open-label, non-randomised, confirmatory Phase 3b study at 48 Chinese hospitals used a single-arm design. Eligible patients received savolitinib 400 mg (body weight <50 kg) or 600 mg (body weight ≥50 kg). Previously treated and treatment-naïve cohorts had a once-daily dosing frequency. The primary endpoint was objective response rate (ORR) assessed by an Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumours v1·1 criteria. The trial is registered with ClinicalTrials.gov, NCT04923945, and has been completed. Findings: From Aug 31, 2021, to Nov 30, 2024, 166 patients were enrolled. In previously treated patients (N = 79), median follow-up was 25·1 months; IRC-assessed ORR, 42% (95% confidence interval [CI] 31%-53%); IRC-assessed median PFS, 13·7 months (95% CI 8·3-17·9), and median OS, 25·3 months (95% CI 20·5-30·5). Among treatment-naïve patients (N = 87), with a median follow-up of 34·5 months, ORR was 62% (95% CI 51%-72%); PFS, 13·7 months (95% CI 8·5-16·6); and OS, 28·3 months (95% CI 17·5-not estimated). Grade ≥3 treatment-related adverse events occurred in 62% of patients and were manageable. Interpretation: Savolitinib demonstrated robust and durable efficacy in patients with Funding: HUTCHMED, AstraZeneca.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.